MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-29-2025
DBV Technologies S.A. Operating Cash Flow 2011-2026 | DBVT
Annual Operating Cash Flow DBV Technologies S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -104 M | -79.7 M | -55.7 M | -108 M | -166 M | -148 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -55.7 M | -166 M | -110 M |
Quarterly Operating Cash Flow DBV Technologies S.A.
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -19.7 M | - | - | -34.7 M | - | - | -20.8 M | - | -31.8 M | - | -1.48 M | - | -89.5 M | - | -36.2 M | - | -132 M | -89.8 M | -49.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.48 M | -132 M | -50.6 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-95.2 M | $ 18.24 | -1.41 % | $ 2.68 B | USA |
 |
Amgen
AMGN
|
11.5 B | $ 344.45 | 0.75 % | $ 185 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
180 M | $ 73.14 | 5.5 % | $ 9.78 B | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Biogen
BIIB
|
2.88 B | $ 178.43 | -0.81 % | $ 26 B | USA |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.7 | 3.85 % | $ 17 M | USA |
 |
Adagene
ADAG
|
-29.7 M | $ 2.87 | 4.36 % | $ 162 M | China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.11 | -2.05 % | $ 7.48 B |  Australia |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Burford Capital Limited
BUR
|
181 M | $ 9.77 | 0.83 % | $ 1.59 B | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-23.4 M | $ 1.39 | -1.42 % | $ 261 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 222.86 | -1.43 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 4.12 | 2.74 % | $ 8.96 B |  Israel |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 109.1 | -4.09 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
-97.2 M | - | - | $ 269 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.39 | 1.09 % | $ 355 M | Britain |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Cardiff Oncology
CRDF
|
-37.7 M | $ 1.75 | -0.29 % | $ 83.4 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Compugen Ltd.
CGEN
|
49.6 M | $ 1.85 | 0.54 % | $ 166 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
-141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
295 M | $ 14.11 | 3.14 % | $ 4.36 B | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-52 M | $ 6.64 | 0.91 % | $ 1.37 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Beam Therapeutics
BEAM
|
-347 M | $ 27.95 | 1.19 % | $ 2.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-141 M | - | 0.49 % | $ 251 B |  Cayman-islands |